![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions about Oxford Biomedica Plc (OXB) over the past week reveal a heightened focus on the possibility of a takeover, amidst uncertainty surrounding the company's share price and recent trading patterns. Many investors express concerns over perceived manipulation of the stock price, with comments suggesting that there seems to be a cap on the share price, limiting upward movement and potentially making the company more attractive for a suitor. Notably, one commenter stated, "the behavior of the company hasn't appeared to be helping their share price," reflecting frustration over stagnant growth and market performance.
Financially, there is optimism amongst investors regarding potential revenue growth, with predictions of around £180 million in sales for next year anticipated. However, there is also skepticism about future valuations and potential acquisition prices, with quotes like "a bid of £7-9 being anything close to a successful bid" illustrating divided sentiment on share value realization in the event of a takeover. Overall, while there are discussions about the benefits of remaining independent and growing as a key player in the CDMO sector, the consensus leans towards apprehension regarding the company's vulnerability to opportunistic bids, as highlighted by one investor's remarks regarding "time will tell—both with the takeover hypothesis and the price."
Investors are observing the ongoing negotiations and strategic moves by major shareholders and potential acquirers, with many eager for clarity on OXB’s trajectory and market positioning as the year draws to a close.
Show more
Oxford Biomedica Plc (OXB), a company leading in cell and gene therapy contract development and manufacturing, recently announced an update regarding its total voting rights, which now stands at 105,938,933 ordinary shares as of November 30, 2024. This follows previous disclosures earlier in the month, confirming a consistent share structure without treasury shares. The total number of voting rights is crucial for shareholders who need to assess their interests in the company, in accordance with Financial Conduct Authority regulations.
In a strategic move, OXB has appointed Colin Bond as a Non-Executive Director, effective January 1, 2025, as part of the company's succession planning on its board. Bond brings substantial experience from the biopharma sector, having previously served as CFO of Sandoz, which strengthens OXB's governance as it navigates its growth trajectory. Furthermore, Oxford Biomedica is hosting a free webinar on December 9, 2024, focusing on innovations in viral vector manufacturing, underscoring its commitment to advancing research and development through automation technologies.
Show more
It will be the numbers that dominate the debate on Monday. We are still in a cash-burn situation so however many good opportunities we have unless we can get them to pay we're just potential buzzard bait. Rights issue? |
Well if there are any market moving surprises in store for us on Monday the market doesnt seem to be expecting them. |
Yes we are: |
Day number 4 on my countdown pb. They are on a PR offensive. If any of their lines eventually works out then happy days. |
Apologies, it's a bad linkHTTps://ir.kyver |
Not sure if we're involved?HTTps://ir. |
OXB...a much better company than Oxford Biomedica ever was! |
What a waste of energy and money. |
Market doesn't like companies that put their efforts into fripperies such as name/logo/etc. changing. |
After that damp squib, 3 working days to go and my selection for bronze position is GeoVax. |
I have to say Dom, that I'm less than thrilled. |
Well that should fix the undervaluing..... just what we have all been waiting for. |
Oovarvo - (vic reeves) |
Excelcia!? |
At least it's not Consignia... |
They are recognised through the industry as OXB, so makes sense to me. They obviously don’t think the Oxford name adds any prestige within biotech. ‘Oxford’ probably seems stuffy, old fashioned and ‘anti-agile |
Strange rebranding? Dropping "Oxford" and "Biomedica" for it's ticker symbol? If you wanted to rebrand wouldn't you go all out for a more imaginative name? |
Massive news OXB to be rebranded as .....OXB Oxford Biomedica PLC - Oxford Biomedica rebrands as OXB #OXB @OxfordBioMedic HTTps://www.voxmarke |
P - I really don't know - I do wish Beam would make it clearer. I have a selection of papers to read :¬( but it will have to wait for tomorrow or later. At the moment I'm wondering whether electroporation is used to prepare the package, and the lentivirus to deliver it to the patient. |
Congratulations Harry. You probably haven't noticed but on every day that since you've been opening your Advent Calendar buy volume has exceeded sales. We need you on the Board as a non exec! |
supernumerary, I think you have sorted it out - It is a 2 stage process. T cells are base-edited with various things to make them invisible to the host (to make them allogenic), then transduced with a lentiviral vector to add the anti-CD7 CAR. |
Page 121 of this presentation for example: But later on P18 mentions a Lentiviral CAR, so I think there may be a step in the process I don't understand. To put it mildly :¬) |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 424.00 |
Offer Price | 426.50 |
Open | 422.50 |
Shares Traded | 65,325 |
Last Trade | 16:35:23 |
Low - High | 421.50 - 429.00 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.43 |
Market Cap | 446.2M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions